SCHEMBL5887019

SCHEMBL5887019

COC(=O)c1ccc(CNC(=O)c2ccc(-n3c(=O)ccc4c(C)nc(N5CCN(C(=O)Cc6ccccc6)CC5)nc43)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
MAPK8 P45983 5/20 0.40
MAPK9 P45984 2/20 0.40
MAPK10 P53779 2/20 0.40
GBA1 P04062 1/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 5/20 0.39
HSD17B10 Q99714 3/20 0.39
POLB P06746 2/20 0.39
CYP2C19 P33261 1/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
TP53 P04637 1/20 0.38
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886979 0.95 GBA1 (0.44) ALDH1A1GBA1SMN1; SMN2MEN1KMT2A
SCHEMBL5886700 0.91 MGLL (0.42) ALDH1A1MAPK8MAPK9MAPK10SMN1; SMN2
SCHEMBL5886804 0.91 SMN1; SMN2 (0.42) ALDH1A1MAPK8MAPK9MAPK10SMN1; SMN2
SCHEMBL5886964 0.91 MAPK8 (0.45) ALDH1A1MAPK8MAPK9MAPK10SMN1; SMN2
SCHEMBL5886912 0.91 ME2 (0.43) ALDH1A1GBA1SMN1; SMN2MEN1KMT2A
SCHEMBL5887021 0.90 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2MAPTHSD17B10HPGD
SCHEMBL5887578 0.90 SMN1; SMN2 (0.42) ALDH1A1MAPK8MAPK9MAPK10SMN1; SMN2
SCHEMBL5887151 0.90 GBA1 (0.39) ALDH1A1MAPK8GBA1SMN1; SMN2MEN1
SCHEMBL5886997 0.90 ALDH1A1 (0.49) ALDH1A1MAPK8MAPK9MAPK10SMN1; SMN2
SCHEMBL5887428 0.89 SMN1; SMN2 (0.42) ALDH1A1MAPK8MAPK9MAPK10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP ALDH1A1 1860/4885MAPK8 770/4885MAPK9 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.